fda compounding curbs

US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs — Photo by Afif Ramdhasuma on Pexels

Stop Losing Access To Prescription Weight Loss

The FDA’s removal of semaglutide, tirzepatide and liraglutide from the 503B bulk-drug list will likely cut patient access by up to 30%, forcing pharmacies to shift to pricier direct-vendor channels. This change follows concerns about sterility, counterfeit risk and the growing demand for GLP-1 weight-loss therapies. Medical Disclaimer: This